These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 19183340)

  • 1. Mechanism of action of metformin in nonalcoholic steatohepatitis.
    Mascitelli L; Pezzetta F; Goldstein MR
    Aliment Pharmacol Ther; 2009 Mar; 29(5):602-3; author reply 603-4. PubMed ID: 19183340
    [No Abstract]   [Full Text] [Related]  

  • 2. Therapeutic trials in nonalcoholic steatohepatitis: insulin sensitizers and related methodological issues.
    Ratziu V; Caldwell S; Neuschwander-Tetri BA
    Hepatology; 2010 Dec; 52(6):2206-15. PubMed ID: 21105109
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Metformin use in children with nonalcoholic fatty liver disease: an open-label, 24-month, observational pilot study.
    Nobili V; Manco M; Ciampalini P; Alisi A; Devito R; Bugianesi E; Marcellini M; Marchesini G
    Clin Ther; 2008 Jun; 30(6):1168-76. PubMed ID: 18640473
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical trial: insulin-sensitizing agents may reduce consequences of insulin resistance in individuals with non-alcoholic steatohepatitis.
    Idilman R; Mizrak D; Corapcioglu D; Bektas M; Doganay B; Sayki M; Coban S; Erden E; Soykan I; Emral R; Uysal AR; Ozden A
    Aliment Pharmacol Ther; 2008 Jul; 28(2):200-8. PubMed ID: 18445142
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Metformin reverses fatty liver disease in obese, leptin-deficient mice.
    Lin HZ; Yang SQ; Chuckaree C; Kuhajda F; Ronnet G; Diehl AM
    Nat Med; 2000 Sep; 6(9):998-1003. PubMed ID: 10973319
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Drug therapy for nonalcoholic fatty liver disease].
    Shen W
    Zhonghua Gan Zang Bing Za Zhi; 2005 Feb; 13(2):139. PubMed ID: 15727706
    [No Abstract]   [Full Text] [Related]  

  • 7. Meta-analysis: insulin sensitizers for the treatment of non-alcoholic steatohepatitis.
    Rakoski MO; Singal AG; Rogers MA; Conjeevaram H
    Aliment Pharmacol Ther; 2010 Nov; 32(10):1211-21. PubMed ID: 20955440
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Use of insulin sensitizers in NASH.
    Khashab M; Chalasani N
    Endocrinol Metab Clin North Am; 2007 Dec; 36(4):1067-87; xi. PubMed ID: 17983937
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Metformin in non-alcoholic steatohepatitis.
    Marchesini G; Brizi M; Bianchi G; Tomassetti S; Zoli M; Melchionda N
    Lancet; 2001 Sep; 358(9285):893-4. PubMed ID: 11567710
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Current biochemical studies of non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH) suggest a new therapeutic approach.
    Hookman P; Barkin JS
    Am J Gastroenterol; 2003 Feb; 98(2):495-9. PubMed ID: 12591075
    [No Abstract]   [Full Text] [Related]  

  • 11. Metformin, vitamin E, and diet for patients with nonalcoholic fatty liver disease.
    Kadayifci A; Merriman RB
    Am J Gastroenterol; 2006 Jun; 101(6):1396; author reply 1396-7. PubMed ID: 16771968
    [No Abstract]   [Full Text] [Related]  

  • 12. Nonalcoholic hepatic steatosis in Zucker diabetic rats: spontaneous evolution and effects of metformin and fenofibrate.
    Forcheron F; Abdallah P; Basset A; del Carmine P; Haffar G; Beylot M
    Obesity (Silver Spring); 2009 Jul; 17(7):1381-9. PubMed ID: 19553925
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Metformin versus dietary treatment in nonalcoholic hepatic steatosis: a randomized study.
    Garinis GA; Fruci B; Mazza A; De Siena M; Abenavoli S; Gulletta E; Ventura V; Greco M; Abenavoli L; Belfiore A
    Int J Obes (Lond); 2010 Aug; 34(8):1255-64. PubMed ID: 20179669
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Metformin in polycystic ovary syndrome.
    Targher G; Lippi G; Moghetti P
    N Engl J Med; 2008 Apr; 358(17):1867; author reply 1868. PubMed ID: 18437728
    [No Abstract]   [Full Text] [Related]  

  • 15. Nonalcoholic steatohepatitis: role of leptin in pathogenesis and benefits of metformin in treatment.
    Kadayifçi A
    Am J Gastroenterol; 2003 Oct; 98(10):2330; author reply 2330-1. PubMed ID: 14572592
    [No Abstract]   [Full Text] [Related]  

  • 16. [Insulin sensitizer--anti-diabetic drugs, metformin and pioglitazone that can improve insulin resistance].
    Korenaga M; Kawaguchi K; Korenaga K; Uchida K; Sakaida I
    Nihon Rinsho; 2006 Jun; 64(6):1157-64. PubMed ID: 16768125
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Metformin plus pentoxifylline versus prescriptive diet in non-alcoholic steatohepatitis (NASH): a randomized controlled pilot trial.
    Sturm N; Bronowicki JP; Maynard-Muet M; Tran A; Heluwaert F; Plages A; Zarski JP
    Gastroenterol Clin Biol; 2009; 33(10-11):984-6. PubMed ID: 19646832
    [No Abstract]   [Full Text] [Related]  

  • 18. Treatment of nonalcoholic steatohepatitis: antioxidants or insulin sensitizers?
    Adams LA; Angulo P
    Clin Gastroenterol Hepatol; 2004 Dec; 2(12):1059-60. PubMed ID: 15625648
    [No Abstract]   [Full Text] [Related]  

  • 19. [Pathogenetic treatment of non-alcoholic steatohepatitis: arguments, efficacy, safety].
    Bueverov AO; Bogomolov PO; Maevskaia MV
    Ter Arkh; 2007; 79(8):88-92. PubMed ID: 17926479
    [No Abstract]   [Full Text] [Related]  

  • 20. Mechanisms involved in the protective effects of metformin against nonalcoholic fatty liver disease.
    Barbero-Becerra VJ; Santiago-Hernandez JJ; Villegas-Lopez FA; Mendez-Sanchez N; Uribe M; Chavez-Tapia NC
    Curr Med Chem; 2012; 19(18):2918-23. PubMed ID: 22519397
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.